Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

The same family of artificial intelligence that powers today's image generators is now being aimed at one of biology's ...

RNA interference is a natural mechanism for living cells to control whether specific genes are being used. Crowned with the ...

RNA interference is a natural mechanism for living cells to control whether specific genes are being used or not.

The Invesco Health Care Fund underperformed its benchmark in Q1 2026 due to poor stock selection in pharmaceuticals. Read the full analysis for more details.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Cancer Res (2026) 86 (7_Supplement): 5894. Papillary thyroid cancer (PTC) is the most common endocrine malignancy, with incidence rising by approximately 3% each year. PTC disproportionately affects ...

The rare disease field is navigating a period of significant turbulence, caught between a “temperamental” FDA and competition for investor attention from mainstream blockbusters like obesity ...

This deal will expand Madrigal’s pipeline in its core focus, MASH. Image credit: Keronn art via ShutterStock.com. Madrigal Pharmaceuticals has inked a deal worth up to $4.4bn with Chinese biotech ...

- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for its first-in-class ivonescimab. Eli Lilly signed two more drug discovery ...

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity. 10 stocks we like better ...